Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -0.25 (-1.61%)
Spread: 0.50 (3.333%)
Open: 15.00
High: 15.50
Low: 14.65
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Sale

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') First Commercial Sale of Synature Product ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its Progeny(R)venture company Synature, which offers a new and innovative approach to onlinemarketing, has secured its first commercial sale with a leading player in theworld's most active markets for package holidays and other leisure travelservices. Together they have launched Holiday Matchmaker, a new way for holidaybuyers to find their ideal destination based on recommendations from like-mindedpeople. This is the first commercial sale of Synature's unique patentedtechnology qubox(TM). Holiday Matchmaker utilises Synature's "attitudinal matching" approach todevelop principles derived from constructivist psychology to measure a person'sfeelings on a particular subject - in this case holidays - and thereby connectweb users to relevant content. Feelings are measured in a fun, engaging wayusing Synature's unique proprietary technology qubox(TM), to complete an online'questionnaire'. The results are then processed with state-of-the-art patternrecognition algorithms, derived from research at the University of Cambridge,UK, to provide personalised recommendations. Thousands of users of the customer's website have taken part in a surveyspecifically designed for the launch of the Holiday Matchmaker, which providesrecommendations based entirely on the opinions of an "online jury". The recommendation system uses a scientific measure of like-mindedness to ensurea client's holiday suggestions come from people with compatible views. Thesystem provides suggestions in multiple categories, including "essential picks","dream holidays" and "quirky choices". John Woods, Chief Executive of Synature, commented: "The Holiday Matchmaker is a new way of searching for a travel product. Itsresults are based on the unbiased opinions of a like-minded peer group. Whereasprevious generations of search and personalisation technology have struggledwith complex products such as travel, our approach built on like-mindedness andusing the power of the social internet takes this product complexity in itsstride. We can even tackle hypothetical questions, such as the idea ofrecommending a 'dream holiday'." Andrew Newland, Chief Executive of ANGLE plc, added: "We are delighted that Synature has secured its first commercial sale with aleading player in the holiday market. The Synature qubox(TM)technology has wideapplication in many online markets and we look forward to further developments." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Synature +44 (0)8701 909550John Woods, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors: About Synature Synature (www.synature.com) was created by ANGLE in early 2005 to commercialiseintellectual property developed by a Cambridge-based team which offers a newapproach to online target marketing. The company has developed this"attitudinal matching" approach into an ASP service offering advanced socialsearch functionality usable by all types of website including e-commerce, socialnetworks, portals and content sites. About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.